Total Payments
$71,224
2024 Payments
$7,040
Companies
43
Transactions
583
Medicare Patients
4,292
Medicare Billing
$4.1M
Payment Breakdown by Category
Other$26,090 (36.6%)
Consulting$25,860 (36.3%)
Food & Beverage$12,413 (17.4%)
Travel$6,691 (9.4%)
Education$169.93 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $25,860 | 8 | 36.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $24,890 | 13 | 34.9% |
| Food and Beverage | $12,413 | 541 | 17.4% |
| Travel and Lodging | $6,691 | 17 | 9.4% |
| Honoraria | $1,200 | 1 | 1.7% |
| Education | $169.93 | 3 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $56,623 | 67 | $0 (2024) |
| Amgen Inc. | $3,368 | 96 | $0 (2024) |
| UCB, Inc. | $1,605 | 28 | $0 (2024) |
| Horizon Therapeutics plc | $1,540 | 26 | $0 (2023) |
| Janssen Biotech, Inc. | $1,382 | 42 | $0 (2024) |
| ABBVIE INC. | $1,075 | 44 | $0 (2024) |
| PFIZER INC. | $857.16 | 40 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $857.02 | 39 | $0 (2024) |
| Lilly USA, LLC | $648.46 | 38 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $426.36 | 18 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $7,040 | 93 | Boehringer Ingelheim Pharmaceuticals, Inc. ($2,939) |
| 2023 | $9,213 | 88 | Boehringer Ingelheim Pharmaceuticals, Inc. ($7,187) |
| 2022 | $16,011 | 80 | Boehringer Ingelheim Pharmaceuticals, Inc. ($14,570) |
| 2021 | $19,047 | 89 | Boehringer Ingelheim Pharmaceuticals, Inc. ($18,044) |
| 2020 | $10,823 | 42 | Boehringer Ingelheim Pharmaceuticals, Inc. ($8,100) |
| 2019 | $7,734 | 115 | Boehringer Ingelheim Pharmaceuticals, Inc. ($5,783) |
| 2018 | $1,288 | 75 | Amgen Inc. ($359.68) |
| 2017 | $68.51 | 1 | E.R. Squibb & Sons, L.L.C. ($68.51) |
All Payment Transactions
583 individual payment records from CMS Open Payments — Page 1 of 24
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,800.00 | General |
| 12/19/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $15.01 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/17/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug), UPTRAVI | Food and Beverage | In-kind items and services | $14.49 | General |
| Category: Cardiology | ||||||
| 12/12/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $23.00 | General |
| 12/12/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $21.67 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/10/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $25.75 | General |
| Category: Dermatology | ||||||
| 12/03/2024 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Food and Beverage | In-kind items and services | $23.77 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 11/21/2024 | Janssen Biotech, Inc. | SIMPONI ARIA (Biological), TREMFYA | Food and Beverage | In-kind items and services | $101.77 | General |
| Category: Immunology | ||||||
| 11/21/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $24.12 | General |
| Category: Immunology | ||||||
| 11/19/2024 | UCB, Inc. | — | Food and Beverage | In-kind items and services | $118.75 | General |
| 11/19/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $114.14 | General |
| 11/17/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $148.97 | General |
| Category: Inflammation | ||||||
| 11/16/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $123.59 | General |
| Category: Immunology | ||||||
| 11/16/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $41.60 | General |
| Category: Immunology | ||||||
| 11/15/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $138.60 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/15/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $22.29 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/13/2024 | UCB, Inc. | — | Food and Beverage | In-kind items and services | $69.44 | General |
| 11/12/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $12.45 | General |
| Category: Immunology | ||||||
| 11/11/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Consulting Fee | Cash or cash equivalent | $1,400.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/07/2024 | SCILEX PHARMACEUTICALS INC. | GLOPERBA (Drug) | Food and Beverage | In-kind items and services | $23.01 | General |
| Category: Analgesic | ||||||
| 11/05/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $34.73 | General |
| Category: Immunology | ||||||
| 10/31/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $20.32 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 10/24/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $22.00 | General |
| Category: IMMUNOLOGY | ||||||
| 10/22/2024 | Alexion Pharmaceuticals, Inc. | STRENSIQ (Biological) | Food and Beverage | In-kind items and services | $20.04 | General |
| Category: Rare Disease | ||||||
| 10/17/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,000.00 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 17 | 766 | 105,660 | $3.3M | $1.0M |
| 2022 | 16 | 743 | 98,269 | $2.9M | $945,936 |
| 2021 | 14 | 645 | 62,438 | $1.9M | $644,534 |
| 2020 | 42 | 2,138 | 97,533 | $3.6M | $1.5M |
Total Patients
4,292
Total Services
363,900
Medicare Billing
$4.1M
Procedure Codes
89
All Medicare Procedures & Services
89 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2023 | 22 | 21,547 | $1.1M | $225,982 | 21.0% |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 12 | 6,825 | $573,300 | $225,177 | 39.3% |
| J0717 | Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 18 | 55,600 | $889,600 | $216,714 | 24.4% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 73 | 7,560 | $234,360 | $138,813 | 59.2% |
| J3111 | Injection, romosozumab-aqqg, 1 mg | Office | 2023 | 14 | 12,180 | $182,700 | $97,406 | 53.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 232 | 491 | $116,367 | $43,635 | 37.5% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 59 | 374 | $123,420 | $36,296 | 29.4% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 28 | 202 | $30,300 | $11,092 | 36.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 77 | 77 | $30,646 | $9,107 | 29.7% |
| 76881 | Complete ultrasound scan of joint | Office | 2023 | 55 | 120 | $27,600 | $4,923 | 17.8% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 88 | 308 | $10,780 | $3,131 | 29.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 17 | 22 | $7,722 | $3,045 | 39.4% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 14 | 105 | $7,770 | $2,217 | 28.5% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 13 | 142 | $6,532 | $1,644 | 25.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 18 | 20 | $3,120 | $1,323 | 42.4% |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | Office | 2023 | 13 | 72 | $1,296 | $311.72 | 24.1% |
| J1020 | Injection, methylprednisolone acetate, 20 mg | Office | 2023 | 13 | 15 | $135.00 | $60.44 | 44.8% |
| J0717 | Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2022 | 18 | 53,200 | $827,600 | $240,097 | 29.0% |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2022 | 12 | 5,650 | $486,600 | $195,208 | 40.1% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2022 | 22 | 16,141 | $807,050 | $188,946 | 23.4% |
| J3111 | Injection, romosozumab-aqqg, 1 mg | Office | 2022 | 13 | 15,540 | $233,100 | $115,545 | 49.6% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 63 | 5,880 | $182,280 | $100,181 | 55.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 226 | 570 | $138,405 | $51,916 | 37.5% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 57 | 211 | $65,990 | $21,356 | 32.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 74 | 74 | $26,644 | $8,524 | 32.0% |
About Dr. Firas Kassab, M.D
Dr. Firas Kassab, M.D is a Rheumatology healthcare provider based in Charlotte, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/27/2007. The National Provider Identifier (NPI) number assigned to this provider is 1366649014.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Firas Kassab, M.D has received a total of $71,224 in payments from pharmaceutical and medical device companies, with $7,040 received in 2024. These payments were reported across 583 transactions from 43 companies. The most common payment nature is "Consulting Fee" ($25,860).
As a Medicare-enrolled provider, Kassab has provided services to 4,292 Medicare beneficiaries, totaling 363,900 services with total Medicare billing of $4.1M. Data is available for 4 years (2020–2023), covering 89 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Location Charlotte, NC
- Active Since 06/27/2007
- Last Updated 12/01/2021
- Taxonomy Code 207RR0500X
- Entity Type Individual
- NPI Number 1366649014
Products in Payments
- OFEV (Drug) $33,133
- KRYSTEXXA (Biological) $3,114
- Enbrel (Biological) $1,072
- TREMFYA (Drug) $907.54
- XELJANZ (Drug) $768.76
- TALTZ (Drug) $648.46
- COSENTYX (Biological) $521.37
- Cimzia (Drug) $479.79
- BENLYSTA (Biological) $412.07
- SIMPONI ARIA (Biological) $385.25
- Humira (Biological) $345.56
- COSENTYX (Drug) $335.65
- ORENCIA (Biological) $316.77
- SKYRIZI (Biological) $278.41
- Rituxan (Biological) $263.87
- RINVOQ (Biological) $248.81
- TAVNEOS (Drug) $228.50
- SAPHNELO (Biological) $198.89
- Actemra (Biological) $186.88
- EVENITY (Biological) $170.33
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Rheumatology Doctors in Charlotte
Gordon Lam, Md, MD
Rheumatology — Payments: $3.1M
Rheumatology $3.1M
Dr. Andrew Laster, Md, MD
Rheumatology — Payments: $751,361
Rheumatology $751,361
Dr. Heather Gladue, Do, DO
Rheumatology — Payments: $207,205
Rheumatology $207,205
Dr. Alireza Nami, M.d, M.D
Rheumatology — Payments: $56,705
Rheumatology $56,705
John Brendese, M.d., Facr, M.D., FACR
Rheumatology — Payments: $21,513
Rheumatology $21,513
Dr. Ashley Toci, M.d, M.D
Rheumatology — Payments: $8,229
Rheumatology $8,229